Featured
-
-
Correspondence |
Economic comments on proposal for a novel cancer drug pricing model
- Mark J. C. Nuijten
- & Jan Vis
-
News & Views |
The right to try is embodied in the right to die
A patient's right to obtain medication that will be ineffective against his/her terminal illness and will cause his/her death should also encompass the right of that patient to be prescribed medication that might be ineffective and might cause his/her death. Indeed, the 'right to die' should embody the 'right to try' experimental agents for the treatment of cancer.
- Benjamin A. Cohen-Kurzrock
- , Philip R. Cohen
- & Razelle Kurzrock
-
News & Views |
Generic imatinib — impact on frontline and salvage therapy for CML
Imatinib has revolutionized the treatment of chronic myeloid leukaemia (CML). In 2016, generic imatinib will be introduced into the US market. We analyse the potential impact of this new product on patient care and optimal CML therapy, and comment on the effect that distorted cancer drug pricing in the USA will have on treatment for patients with limited therapeutic options.
- Larry Gorkin
- & Hagop Kantarjian
-
News & Views |
Putting a price on cancer
A survey on the official prices of 31 cancer drugs across 18 countries, published by Vogler and colleagues, has revealed substantial differences in price for the same drug in different countries. Herein, we discuss inequalities in the access to cancer care and raise some challenging questions.
- Richard Sullivan
- & Ajay Aggarwal
